Li Z, Wu T, Zheng B, Chen L. Individualized precision treatment: Targeting TAM in HCC.
Cancer Lett 2019;
458:86-91. [PMID:
31129147 DOI:
10.1016/j.canlet.2019.05.019]
[Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Revised: 04/28/2019] [Accepted: 05/15/2019] [Indexed: 12/24/2022]
Abstract
Tumor-associated macrophage (TAM) plays a prominent role in inflammatory microenvironment which contributes to hepatocellular carcinoma (HCC) progress by presenting M1 and M2 polarization. HCC, which is highly associated with inflammation, always leads to poor prognosis for recurrence and metastasis. TAMs with M2 polarization induce cellular proliferation, angiogenesis, epithelial-mesenchymal transition (EMT) in HCC. Furthermore, it also interacts with other immune cell clusters which leads to the resistance in targeted therapy and immunotherapy. This article reviews studies on the role of TAM to affect HCC treatment and provides insight into the potential individualized precision monotherapy or combination therapy in HCC.
Collapse